ArticleBMC infectious diseases2026
Assessing N. gonorrhoeae prevalence and testing capacity for new treatment rollout: a scoping review for Cambodia, Thailand, Vietnam and South Africa.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeisseria gonorrhoeae, a major cause of sexually transmitted bacterial infections, poses a significant public health challenge, particularly due to rising antimicrobial resistance (AMR). Regions such as South-East Asia and Africa may face substantial and possibly rising burdens of gonorrhoea, though the full extent remains unclear due to limited diagnostic testing, underreporting, and gaps in aetiological and antimicrobial resistance surveillance - especially in countries lacking population-based prevalence estimates. Addressing deficiencies in data from these regions, particularly those with limited diagnostic infrastructure that are underrepresented in population-based studies, is critical for advancing global sexually transmitted infections (STIs) management and the implementation of new treatments.
methodsThis scoping review focused on the prevalence and reported resistance patterns of N. gonorrhoeae across four target countries: Cambodia, Thailand, Vietnam and South Africa. A systematic literature search using PubMed and WHO reports from 2019 to 2023 was conducted, with studies screened based on predefined inclusion and exclusion criteria. Data on prevalence, susceptibility profiles, and laboratory methodologies were extracted and analysed.
resultsOf the 217 articles identified, 29 were included, with South Africa contributing 83% of the studies. No eligible studies were identified from Cambodia. Prevalence rates varied, with the highest observed in one study among men with urethral discharge syndrome in South Africa (87.6% CI95% 85.2-89.9%). Antibiotic susceptibility data were limited to a small subset of articles (4/29, 13.8%), with resistance ranging from ≈78% for ciprofloxacin to ≈1% for cefixime. Laboratory methods primarily employed nucleic acid amplification testing, with limited use of phenotypic testing anywhere, hindering comprehensive AMR monitoring.
conclusionThis scoping review confirms substantial data gaps on N. gonorrhoeae prevalence and antimicrobial resistance across the studied regions, with Cambodia contributing no eligible studies and Thailand and Vietnam remaining underrepresented in published literature. National programs and international partners should prioritise sentinel culture capacity and standardised antimicrobial susceptibility testing and genotypic testing to inform treatment guidelines, detect emerging resistance patterns, and inform public health interventions in these high-burden regions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.